| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
2'-O-MOE-rC does not have a specific biological target itself. It is a building block for oligonucleotide synthesis. The MOE modification enhances the drug-like properties of the resulting oligonucleotides, including nuclease resistance and binding affinity.
|
|---|---|
| ln Vitro |
In vitro, 2'-O-MOE-rC is used as a monomer in the synthesis of oligonucleotides. The resulting MOE-modified oligonucleotides exhibit enhanced stability and target binding affinity.
|
| ln Vivo |
In vivo, 2'-O-MOE-rC is not used as a therapeutic agent itself. However, oligonucleotides synthesized using this building block have been used in vivo as therapeutic agents, with the MOE modification improving their pharmacokinetic properties.
|
| Enzyme Assay |
In vitro non-cell-based assays for 2'-O-MOE-rC typically involve its use in standard oligonucleotide synthesis protocols. The compound is coupled to a growing oligonucleotide chain, and the purity and identity of the synthesized oligonucleotides are confirmed by HPLC and mass spectrometry.
|
| Cell Assay |
In vitro cell-based assays are not typically performed with 2'-O-MOE-rC itself, as it is a synthetic intermediate. However, the MOE-modified oligonucleotides synthesized from it are tested in cell-based assays to evaluate their efficacy in modulating target gene expression.
|
| Animal Protocol |
In vivo animal experiments are not conducted with 2'-O-MOE-rC directly. Instead, MOE-modified oligonucleotides synthesized using this building block are administered to animal models to study their pharmacokinetics, pharmacodynamics, and therapeutic efficacy.
|
| ADME/Pharmacokinetics |
2'-O-MOE-rC has a molecular weight of 907.99 g/mol and the formula C49H58N5O10P. It is a nucleoside phosphoramidite and is stored under appropriate conditions. Its purity is typically 97%.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for 2'-O-MOE-rC are not provided, as it is a chemical building block. However, oligonucleotides containing MOE modifications have been extensively studied and are generally well-tolerated.
|
| References |
|
| Additional Infomation |
2'-O-MOE-rC is a modified nucleoside used in the synthesis of therapeutic oligonucleotides. The MOE modification is a key feature of second-generation antisense oligonucleotides. It is intended for research use.
|
| Molecular Formula |
C49H58N5O10P
|
|---|---|
| Molecular Weight |
907.986093997955
|
| Exact Mass |
877.381
|
| CAS # |
251647-54-8
|
| PubChem CID |
127262586
|
| Appearance |
White to light yellow solid powder
|
| LogP |
10.57
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
65
|
| Complexity |
1550
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(C)N(C(C)C)P(OCCC#N)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N2C=CC(=NC2=O)NC(=O)C3=CC=CC=C3)COC(C4=CC=CC=C4)(C5=CC=C(C=C5)OC)C6=CC=C(C=C6)OC
|
| InChi Key |
IAFVTVZPQIFRAU-NXPFYNPLSA-N
|
| InChi Code |
InChI=1S/C49H58N5O10P/c1-34(2)54(35(3)4)65(62-30-14-28-50)64-44-42(63-47(45(44)60-32-31-57-5)53-29-27-43(52-48(53)56)51-46(55)36-15-10-8-11-16-36)33-61-49(37-17-12-9-13-18-37,38-19-23-40(58-6)24-20-38)39-21-25-41(59-7)26-22-39/h8-13,15-27,29,34-35,42,44-45,47H,14,30-33H2,1-7H3,(H,51,52,55,56)/t42-,44-,45-,47-,65?/m1/s1
|
| Chemical Name |
N-[1-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxy-3-(2-methoxyethoxy)oxolan-2-yl]-2-oxopyrimidin-4-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~110.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1013 mL | 5.5067 mL | 11.0133 mL | |
| 5 mM | 0.2203 mL | 1.1013 mL | 2.2027 mL | |
| 10 mM | 0.1101 mL | 0.5507 mL | 1.1013 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
